An Analysis of Extended Survival in Patients With Amyotrophic Lateral Sclerosis Treated With Riluzole
Authors:
- Vincent MeiningerVMVincent Meininger
- Phillipe ZeisserPZPhillipe Zeisser
- Theodore MunsatTMTheodore Munsat
Open Access
- 1 April 1998
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 55 (4) , 526-528
Abstract
AMYOTROPHIC lateral sclerosis (ALS) is a chronic and debilitating neurodegenerative disease for which no cure is currently available. The clinical syndrome associated with the disease is the result of the degeneration of cortical, bulbar, and medullary motor neurons that enable voluntary motor function. Death is usually the result of respiratory failure. The worldwide incidence of the disease is 1 to 3 cases per 100000 population per year.Keywords
This publication has 4 references indexed in Scilit:
- Dose-ranging study of riluzole in amyotrophic lateral sclerosisThe Lancet, 1996
- The natural history of amyotrophic lateral sclerosisNeurology, 1993
- Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivoNeuroscience Letters, 1992
- A rating scale for amyotrophic lateral sclerosis: Description and preliminary experienceAnnals of Neurology, 1987